Liquidia Corp

Liquidia Corporation is a biopharmaceutical company focused on respiratory and vascular diseases, including pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company operates through its wholly owned subsidiaries, Liquidia Technologies, Inc. and Liquidia PAH, LLC. Liquidia generates revenue from the sale of YUTREPIA (treprostinil) inhalation powder. Additionally, under a promotion agreement with Sandoz Inc. dated August 1, 2018, Liquidia shares profit from the sale of Sandoz's generic treprostinil injection (Treprostinil Injection) in the United States. YUTREPIA is an inhaled dry powder formulation of treprostinil, developed using Liquidia's proprietary PRINT technology. This technology aims to improve treprostinil's therapeutic profile through enhanced deep lung delivery, a low-effort dry-powder inhaler, and the ability to achieve higher dose levels than other marketed inhaled treprostinil therapies. YUTREPIA was approved by the U.S. Food and Drug Administration (FDA) in May 2025 for treating PAH and PH-ILD, with commercialization beginning in June 2025. Liquidia has exclusive rights to commercial activities for Treprostinil Injection in the United States and collaborates with Sandoz on its commercial strategy. Sandoz holds the Abbreviated New Drug Application (ANDA) for Treprostinil Injection and retains all other rights to the product. The company also conducts research, development, and manufacturing of new products. An example is L606, an investigational liposomal formulation of treprostinil, licensed from Pharmosa Biopharm Inc. Liquidia employs a commercial field force targeting healthcare providers and stakeholders involved in treating PAH and PH-ILD in the United States.